Top

Published in:

01-11-2013 | Original Article

TFF3 and survivin expressions associate with a lower survival rate in gastric cancer

Authors: Jia-Rong Meng, Hui-Zhong Tang, Kai-Zong Zhou, Wu-Hong Shen, He-Yi Guo

Published in: Clinical and Experimental Medicine | Issue 4/2013

Abstract

Trefoil factor 3 (TFF3) and survivin with functions of inhibiting apoptosis are involved in the gastric cancer by overexpression. The purpose of this study is to examine the expression of TFF3 and survivin in patients’ tissue samples with gastric cancer and analyze the relationship between the protein expression and the different clinical records. By studying the expressions of TFF3 and survivin in gastric cancer through immunohistochemical staining and examining the survival rate via Kaplan–Meier analysis for gastric cancer patients, we found that the TFF3 and survivin positive expressions have a significant relationship with the lower survival rate comparing to that of negative expressions in the analyzed patients (P < 0.05). And moreover, patients with double positive TFF3 and survivin expressions have the lowest survival rate. TFF3 or survivin positive expression correlates with the lymph node metastasis, metastasis, and TNM stages of gastric cancer. Survival analysis indicates that survival rate has a close relationship with the age, tumor histology, tumor differentiation, degree of infiltration, lymph node metastasis, distant metastasis, and TNM stages (P < 0.01). Our data suggest that TFF3 and survivin expressions play a vital role in gastric cancer development, and these two proteins are important markers for prognosis in gastric cancer. Patients with gastric cancer can increase the survival rate through an earlier diagnosis and appropriate treatment.

Muskett FW, May FE, Westley BR, Feeney J (2003) Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry-Us 42:15139–15147CrossRef

Katoh M (2003) Trefoil factors and human gastric cancer (review). Int J Mol Med 12:3–9PubMed

Liu D, Chinery R, Wilding J, Gullick WJ, Kmiot W, Pignatelli M (1997) Phosphorylation of γ-catenin and epidermal growth-factor receptor by intestinal trefoil factor. Lab Investig 77:557–563PubMed

Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, Hattori T, Wright NA, Bodmer WF, Pignatelli M (1998) Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci 95:3122–3127PubMedCrossRef

Emami S, LeFloch N, Bruynell E, Thim L, May F, Westley B, Rio MC, Mareel M, Gespach C (2001) Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J 15:351–361PubMedCrossRef

Taupin DR, Kinoshita K, Podolsky DK (2000) Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci 97:799–804PubMedCrossRef

Chen YH, Lu Y, DePlaen IG, Wang LY, Tan XD (2000) Transcription factor NF-kB signals antianoikic function of trefoil factor 3 on intestinal epithelial cells. Biochem Biophys Res Commun 274:576–582PubMedCrossRef

Leung WK, Yu J, Chan FK, To KF, Chan MW, Ebert MP, Ng EK, Chung SC, Malfertheiner P, Sung JJ (2002) Expression of trefoil peptides (TFF1, TFF2, and TFF3) in gastric carcinomas, intestinal metaplasia, and non-neoplastic gastric tissues. J Pathol 197:582–588PubMedCrossRef

Yamachika T, Werther JL, Bodian C, Babyatsky M, Tatematsu M, Yamamura Y, Chen A, Itzkowitz S (2002) Intestinal trefoil factor: a marker of poor prognosis in gastric carcinoma. Clin Cancer Res 8:1092–1099PubMed

10.

Ahmed AR, Griffiths AB, Tilby MT, Westley BR, May FE (2012) TFF3 is a normal breast epithelial protein and is associated with differentiated phenotype in early breast cancer but predisposes to invasion and metastasis in advanced disease. Am J Pathol 180:904–916PubMedCrossRef

11.

Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921PubMedCrossRef

12.

Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, Reed JC (1998) IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315–5320PubMed

13.

Anti-Cancer AoC (1999) Diagnosis rules for new common malignant tumors. Peking Union Medicai College Press, Beijing

14.

Tang ZH, Chen HS, Zou ZK, Cai SB, Su HY, Shen HW, We WQ, Lin L, Wang YH (2008) Trefoil factor 4 and CD147 expression in carninogenesis of gastric mucosa and their correlation with angiogenesis. World Chin J Digestol 16:3631–3636

15.

Kirikoshi H, Katoh M (2002) Expression of TFF1, TFF2 and TFF3 in gastric cancer. Int J Oncol 21:655–659PubMed

16.

Moss SF, Lee JW, Sabo E, Rubin AK, Rommel J, Westley BR, May FE, Gao J, Meitner PA, Tavares R, Resnick MB (2008) Decreased expression of gastrokine 1 and the trefoil factor interacting protein TFIZ1/GKN2 in gastric cancer: influence of tumor histology and relationship to prognosis. Clin Cancer Res 14:4161–4167PubMedCrossRef

17.

Rodrigues S, Van Aken E, Van Boxciaer S et al (2003) Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 2003(17):7–16CrossRef

18.

Dhar DK, Wang TC, Tabara H, Tonomoto Y, Maruyama R, Tachibana M, Kubota H, Nagasue N (2005) Expression of trefoil factor family members correlates with patient prognosis and neoangiogenesis. Clin Cancer Res 11:6472–6478PubMedCrossRef

19.

Guleng B, Han J, Yang JQ, Huang QW, Huang JK, Yang XN, Liu JJ, Ren JL (2012) TFF3 mediated induction of VEGF via hypoxia in human gastric cancer SGC-7901 cells. Mol Biol Rep 39:4127–4134PubMedCrossRef

20.

Yu J, Leung WK, Ebert MP, Ng EK, Go MY, Wang HB, Chung SC, Malfertheiner P, Sung JJ (2002) Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer 87:91–97PubMedCrossRef

21.

Lee GH, Joo YE, Koh YS, Chung IJ, Park YK, Lee JH, Kim HS, Choi SK, Rew JS, Park CS, Kim SJ (2006) Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur J Gastroenterol Hepatol 18:957–963PubMedCrossRef

22.

Kania J, Konturek SJ, Marlicz K, Hahn EG, Konturek PC (2003) Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci 48:266–271PubMedCrossRef

23.

Lu CD, Altieri DC, Tanigawa N (1998) Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808–1812PubMed

24.

Da CL, Xin Y, Zhao J, Luo XD (2009) Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions. World J Gastroenterol 15:4055PubMedCrossRef

25.

Bertazza L, Mocellin S, Marchet A, Pilati P, Gabrieli J, Scalerta R, Nitti D (2009) Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J Transl Med 7:111PubMedCrossRef

26.

Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE, Morris JC (2011) Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 10:35PubMedCrossRef

Title: TFF3 and survivin expressions associate with a lower survival rate in gastric cancer
Authors: Jia-Rong Meng
Hui-Zhong Tang
Kai-Zong Zhou
Wu-Hong Shen
He-Yi Guo
Publication date: 01-11-2013
Publisher: Springer Milan
Published in: Clinical and Experimental Medicine / Issue 4/2013
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-012-0210-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide

Vitamin D deficiency affects the immunity against Mycobacterium tuberculosis infection in mice

Influence of IL17A polymorphisms (rs2275913 and rs3748067) on the susceptibility to ulcerative colitis

Gamma-secretase inhibitor DAPT suppresses glioblastoma growth via uncoupling of tumor vessel density from vessel function

Reduced CD19 expression and decreased memory B cell numbers in transient hypogammaglobulinemia of infancy

Aberrant activation of Hedgehog pathway in Nasopharyngeal carcinoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials